95 related articles for article (PubMed ID: 15835912)
1. The catalytically active serine protease domain of human complement factor I.
Tsiftsoglou SA; Willis AC; Li P; Chen X; Mitchell DA; Rao Z; Sim RB
Biochemistry; 2005 Apr; 44(16):6239-49. PubMed ID: 15835912
[TBL] [Abstract][Full Text] [Related]
2. Only the light chain is sufficient for the serine protease function of the membrane bound form of factor I on a xeno-surface.
Fukuta D; Miyagawa S; Kubo T; Kusama T; Shirasu A; Hattori H; Shirakura R
Transpl Immunol; 2004 Jan; 12(2):109-14. PubMed ID: 14967308
[TBL] [Abstract][Full Text] [Related]
3. Identification of the C3b binding site in a recombinant vWF-A domain of complement factor B by surface-enhanced laser desorption-ionisation affinity mass spectrometry and homology modelling: implications for the activity of factor B.
Hinshelwood J; Spencer DI; Edwards YJ; Perkins SJ
J Mol Biol; 1999 Nov; 294(2):587-99. PubMed ID: 10610782
[TBL] [Abstract][Full Text] [Related]
4. Possible arrangement of the five domains in human complement factor I as determined by a combination of X-ray and neutron scattering and homology modeling.
Chamberlain D; Ullman CG; Perkins SJ
Biochemistry; 1998 Oct; 37(40):13918-29. PubMed ID: 9760226
[TBL] [Abstract][Full Text] [Related]
5. Human complement factor I does not require cofactors for cleavage of synthetic substrates.
Tsiftsoglou SA; Sim RB
J Immunol; 2004 Jul; 173(1):367-75. PubMed ID: 15210795
[TBL] [Abstract][Full Text] [Related]
6. Mutations of the type A domain of complement factor B that promote high-affinity C3b-binding.
Hourcade DE; Mitchell LM; Oglesby TJ
J Immunol; 1999 Mar; 162(5):2906-11. PubMed ID: 10072540
[TBL] [Abstract][Full Text] [Related]
7. Complement factor I in health and disease.
Nilsson SC; Sim RB; Lea SM; Fremeaux-Bacchi V; Blom AM
Mol Immunol; 2011 Aug; 48(14):1611-20. PubMed ID: 21529951
[TBL] [Abstract][Full Text] [Related]
8. A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation.
Nilsson SC; Karpman D; Vaziri-Sani F; Kristoffersson AC; Salomon R; Provot F; Fremeaux-Bacchi V; Trouw LA; Blom AM
Mol Immunol; 2007 Mar; 44(8):1835-44. PubMed ID: 17084897
[TBL] [Abstract][Full Text] [Related]
9. Complement component C2, inhibiting a latent serine protease in the classical pathway of complement activation.
Halili MA; Ruiz-Gómez G; Le GT; Abbenante G; Fairlie DP
Biochemistry; 2009 Sep; 48(35):8466-72. PubMed ID: 19642650
[TBL] [Abstract][Full Text] [Related]
10. Recombinant generation of two fragments of the rat complement inhibitory factor H [FH(SCR1-7) and FH(SCR1-4)] and their structural and functional characterization in comparison to FH isolated from rat serum.
Demberg T; Heine I; Götze O; Altermann WW; Seliger B; Schlaf G
Histol Histopathol; 2006 Jan; 21(1):93-102. PubMed ID: 16267790
[TBL] [Abstract][Full Text] [Related]
11. The hyaluronan-binding serine protease from human plasma cleaves HMW and LMW kininogen and releases bradykinin.
Etscheid M; Beer N; Fink E; Seitz R; Johannes D
Biol Chem; 2002 Oct; 383(10):1633-43. PubMed ID: 12452440
[TBL] [Abstract][Full Text] [Related]
12. Human tryptase fibrinogenolysis is optimal at acidic pH and generates anticoagulant fragments in the presence of the anti-tryptase monoclonal antibody B12.
Ren S; Lawson AE; Carr M; Baumgarten CM; Schwartz LB
J Immunol; 1997 Oct; 159(7):3540-8. PubMed ID: 9317153
[TBL] [Abstract][Full Text] [Related]
13. Regulator-dependent mechanisms of C3b processing by factor I allow differentiation of immune responses.
Xue X; Wu J; Ricklin D; Forneris F; Di Crescenzio P; Schmidt CQ; Granneman J; Sharp TH; Lambris JD; Gros P
Nat Struct Mol Biol; 2017 Aug; 24(8):643-651. PubMed ID: 28671664
[TBL] [Abstract][Full Text] [Related]
14. Role of the C3b-binding site on C4b-binding protein in regulating classical pathway C5 convertase.
Rawal N; Pangburn MK
Mol Immunol; 2007 Feb; 44(6):1105-14. PubMed ID: 16979240
[TBL] [Abstract][Full Text] [Related]
15. The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models.
Saunders RE; Abarrategui-Garrido C; Frémeaux-Bacchi V; Goicoechea de Jorge E; Goodship TH; López Trascasa M; Noris M; Ponce Castro IM; Remuzzi G; Rodríguez de Córdoba S; Sánchez-Corral P; Skerka C; Zipfel PF; Perkins SJ
Hum Mutat; 2007 Mar; 28(3):222-34. PubMed ID: 17089378
[TBL] [Abstract][Full Text] [Related]
16. Identification and characterization of human polyserase-3, a novel protein with tandem serine-protease domains in the same polypeptide chain.
Cal S; Peinado JR; Llamazares M; Quesada V; Moncada-Pazos A; Garabaya C; López-Otín C
BMC Biochem; 2006 Mar; 7():9. PubMed ID: 16566820
[TBL] [Abstract][Full Text] [Related]
17. Analysis of binding sites on complement factor I that are required for its activity.
Nilsson SC; Nita I; Månsson L; Groeneveld TW; Trouw LA; Villoutreix BO; Blom AM
J Biol Chem; 2010 Feb; 285(9):6235-45. PubMed ID: 20044478
[TBL] [Abstract][Full Text] [Related]
18. Cleavage of the complement system C3 component by HIV-1 proteinase.
Kisselev AF; Mentele R; von der Helm K
Biol Chem; 1997 May; 378(5):439-42. PubMed ID: 9191031
[TBL] [Abstract][Full Text] [Related]
19. Analysis of binding sites on complement factor I using artificial N-linked glycosylation.
Sanchez-Gallego JI; Groeneveld TW; Krentz S; Nilsson SC; Villoutreix BO; Blom AM
J Biol Chem; 2012 Apr; 287(17):13572-83. PubMed ID: 22393059
[TBL] [Abstract][Full Text] [Related]
20. Investigation of the mechanisms of anti-complement activity in Ixodes ricinus ticks.
Lawrie CH; Sim RB; Nuttall PA
Mol Immunol; 2005 Jan; 42(1):31-8. PubMed ID: 15488941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
